StockNews.AI
ATNM
StockNews.AI
111 days

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

1. A lawsuit is filed against Actinium Pharmaceuticals (ATNM) by an investor. 2. Allegations include failure to disclose critical data for Iomab-B BLA approval. 3. Plaintiffs claim misrepresentation of the company's prospects for FDA approval. 4. Investors can contact Shareholders Foundation for options regarding the lawsuit. 5. The lawsuit pertains to shares bought before October 2022.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations may undermine investor confidence and impact stock value, similar to past cases where lawsuits correlated with significant declines. Historical examples include companies like Valeant Pharmaceuticals, where ongoing litigation similarly hurt investor sentiment.

How important is it?

The lawsuit directly addresses critical aspects of ATNM's operations and leads to legal uncertainty surrounding its Iomab-B BLA application which is crucial for market performance.

Why Short Term?

The immediate impact from legal actions can result in volatility as market reactions to news are often swift. Past instances like the Tesla lawsuit showed that legal challenges can lead to rapid sell-offs in stock prices.

Related Companies

VRTXIBIOBMY
, /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Investors who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) prior to October 2022 and continue to hold any of thoseNYSE: ATNM shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On March 27, 2025, aNYSE: ATNM investor filed a lawsuit against Actinium Pharmaceuticals, Inc. over alleged violations of securities laws. The plaintiff alleged that the Defendants failed to disclose that the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate Sierra's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved, and that as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Those who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) should contact the Shareholders Foundation, Inc. CONTACT:Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. SOURCE Shareholders Foundation, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News